The European Commission highlights our approach to combining thermal imaging and artificial intelligence to make vascular diagnostics more accessible.
We’re proud to share that Kelvin Health features in the European Commission’s State of the Union 2026 — From promise to progress: second year in office.
The report reviews the Commission’s progress towards a more independent, competitive and resilient Europe. Kelvin Health is presented within the section “An innovative Union that leads the industries of the future”, as an example of Bulgarian health innovation and highlights the European programmes supporting its development.
For our team, this inclusion is a meaningful milestone. It brings visibility to our mission and places Bulgarian health technology within a wider discussion about how European research can deliver practical benefits for patients.
What the Commission highlights
The Commission describes Kelvin Health as a Bulgarian HealthTech innovator developing a non-invasive approach to detecting early signs of vascular disease and inflammation through thermal images, artificial intelligence and a smartphone.
The feature connects this approach to an important healthcare challenge. As the report notes, vascular and cardiovascular diseases are a leading cause of death and disability in the European Union. It highlights our mission to advance care through accessible diagnostics and help identify serious health risks early.
One phrase in the report captures the purpose behind these efforts:
“Turning cutting-edge research into practical solutions for patients”
That connection between research and patient needs is central to what we are building. We focus on applying technology to a clear healthcare problem: making the identification of vascular health risks more accessible.
The report also names Horizon Europe and EIT Health as supporters of Kelvin Health. It references our international innovation awards, including Health Tech Innovation of the Year 2022 at MedTech World.
Health technology within Europe’s innovation agenda
A central theme of the report is Europe’s ability to turn scientific expertise into successful products and companies. The Commission connects investment in innovation with stronger industries and improvements in people’s lives.
Artificial intelligence, biotechnology and life sciences feature prominently in this agenda. Through InvestAI, the Commission aims to mobilise €200 billion in public and private AI investment. Its Apply AI Strategy supports the adoption of artificial intelligence in sectors including healthcare and pharmaceuticals.
The report also outlines a plan for the Commission and the European Investment Bank to invest €10 billion in biotechnology and life sciences during 2026 and 2027. This is a sector-wide investment plan. Alongside it, the proposed Biotech Act aims to reduce regulatory complexity and accelerate clinical trials across the EU.
Kelvin Health provides a concrete example within this broader policy discussion: a Bulgarian company applying AI and thermal imaging to a healthcare challenge, with support from European innovation programmes.
A milestone for Kelvin Health
Building health technology requires sustained research, collaboration and attention to the needs of healthcare professionals and patients. Inclusion in the Commission’s report offers an opportunity to acknowledge the people and partnerships supporting that effort.
It also brings attention to Bulgaria’s contribution to European health innovation. We’re proud to be part of that story and to contribute our expertise to the development of more accessible diagnostics.
The report’s emphasis on practical solutions reflects our ambition. As we continue developing the technology, we remain focused on how it can support healthcare professionals and help identify serious health risks earlier.
Read the Kelvin Health feature on page 16 of the English report, or contact our team to learn more and discuss collaboration opportunities.
